Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Yoga, Exercise Associated With Better Survival in Nonmetastatic Breast Cancer

December 7th 2022

Patients with non-metastatic breast cancer undergoing treatment who added yoga to conventional exercises experienced improvements in disease-free survival, overall survival, and long-term quality of life vs those who did conventional exercises alone.

Trastuzumab Deruxtecan Generates PFS, OS Benefit Vs Capecitabine-based Regimens in Pretreated HER2+ Breast Cancer

December 7th 2022

Trastuzumab deruxtecan demonstrated a 64% reduction in the risk of disease progression or death compared with physician's choice of treatment in patients with advanced HER2-positive unresectable and/or metastatic breast cancer who previously received ado-trastuzumab emtansine.

Dr. Abdou on Race and Clinical Outcomes in Breast Cancer

December 7th 2022

Yara Abdou, MD, discusses racial disparities in breast cancer outcomes in patients enrolled to the phase 3 RxPONDER trial.

Breast Cancer Index Risk Scores Are Prognostic for Premenopausal Women With HR+ Breast Cancer Receiving Adjuvant Endocrine Therapy

December 7th 2022

The Breast Cancer Index test reliably identified premenopausal women undergoing adjuvant endocrine therapy for early-stage, hormone receptor–positive breast cancer who would derive benefit from the addition of ovarian function suppression.

Black Women With HR+ Breast Cancer Have Worse Outcomes, Despite Similar Recurrence Scores

December 7th 2022

Non-Hispanic Black patients with hormone receptor–positive/HER2-negative breast cancer were more likely to have worse outcomes vs non-Hispanic White, Asian, and Hispanic patients, according to an analysis of the phase 3 RxPONDER trial.

Benefit of Adjuvant Abemaciclib Increases at 4-Year monarchE Landmark Analysis for Patients With HR+/HER2– High-Risk Early Breast Cancer

December 7th 2022

A clinically meaningful improvement in invasive disease-free survival and distant relapse-free survival was observed with the addition of adjuvant abemaciclib to endocrine therapy in patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer, according to results of a prespecified overall survival analysis of the monarchE study.

Everolimus Plus Adjuvant Endocrine Therapy Fails to Improve iDFS, OS in HR+/HER2- Breast Cancer

December 7th 2022

The addition of 1 year of everolimus to adjuvant endocrine therapy did not demonstrate a statistically significant improvement in invasive disease-free survival or overall survival in patients with high-risk, hormone receptor–positive, HER2-negative breast cancer.

Frontline Ribociclib Plus Endocrine Therapy Provides PFS Benefit in Pre/Perimenopausal HR+/HER2- Advanced Breast Cancer

December 6th 2022

The combination of ribociclib plus endocrine therapy yielded a 46% reduction in the risk of disease progression or death compared with chemotherapy in pre/perimenopausal patients with aggressive hormone receptor–positive/HER2-negative advanced breast cancer.

Chemotherapy Followed by Endocrine Therapy Could Increase Cognitive Impairment in Breast Cancer, Irrespective of Menopausal Status

December 6th 2022

Chemotherapy prior to treatment with endocrine therapy could increase the risk of cancer-related cognitive impairment compared with endocrine therapy alone in women with breast cancer, irrespective of menopausal status.

Racial Disparity Revealed in Prometastatic TME in Women With Residual Breast Cancer After Neoadjuvant Chemo

December 6th 2022

Tumor microenvironment of metastasis doorway density—a biomarker of distant metastatic recurrence—is higher in Black women vs White women with estrogen receptor–positive/HER2-negative breast cancer who have residual disease after neoadjuvant chemotherapy.

Leone Lays Out Research Needs and Treatment Approaches in Male Breast Cancer

December 1st 2022

Dr Leone discusses the distinguishing features of male breast cancer, the benefits and limitations of current treatments, and the importance of raising awareness about this breast cancer subset to propel further research.

Dr. Goetz on the Impact of the PALOMA-2 Trial in ER+/HER2- Breast Cancer

December 1st 2022

Matthew P. Goetz, MD, discusses the impact of the phase 3 PALOMA-2 trial in estrogen receptor–positive/HER2-negative advanced breast cancer.

Dr. Conlin on the Implications of the HER2-Low Subset in Breast Cancer

November 30th 2022

Alison K. Conlin, MD, discusses the inception of the HER2-low breast cancer treatment landscape.

Japan Approves Trastuzumab Deruxtecan for Previously Treated HER2+ Metastatic Breast Cancer

November 28th 2022

Japan’s Ministry of Health, Labor, and Welfare has approved trastuzumab deruxtecan for the treatment of adult patients with HER2-positive unresectable or recurrent breast cancer after prior chemotherapy, which includes trastuzumab and a taxane.

Advances in Breast Cancer Treatment Reshape Treatment Paradigms in 2022

November 21st 2022

The increasing role of antibody-drug conjugates have led to questions of sequencing for patients with HER2-positive breast cancer, whereas new data for first-generation PD-L1 inhibitors, such as pembrolizumab have shaken up the treatment paradigm for others.

Dr. Hurvitz on the Evolution of Targeted Therapies in HER2+ Breast Cancer

November 17th 2022

Sara A. Hurvitz, MD, discusses the evolution of targeted therapies in HER2-positive breast cancer.

Oppong Sheds Light on Racial Disparities in Breast Cancer Diagnosis and Mortality

November 17th 2022

Dr Oppong discusses factors that contribute to the ongoing disparity in breast cancer deaths among Black women vs White women, the importance of increased access to high-quality screening, and the need for more inclusive research efforts to close the gaps in breast cancer diagnosis and care.

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15th 2022

The addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in patients with metastatic triple-negative breast cancer according to updated data from the phase 2 MARIO-3 trial.

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13th 2022

CYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung cancer, triple-negative breast cancer, and bladder cancer cell lines, according to preclinical data.

Rugo Highlights Key Priorities for the Future of Breast Cancer Research

November 10th 2022

Research in breast cancer has led to remarkable progress in the understanding and management of the disease, but the oncology community can always do more to optimize treatment outcomes for patients.